Be on the Move with PHA in 2019! 

2019 is shaping to be an even more exciting year for PHA with events such as the PHA Forum, many new members and special initiatives, not to mention an extension of our work on Social Determinants of Health! 

The PHA Board thanks its many committed members advancing Population Health for individuals and communities every day.  If you are not a PHA member join the Population Health Alliance today.
Fast Approaching - Don't Miss Out!
March 18 - PHA Forum 2019: Creating Value through Engagement & Social Determinant Levers
Join PHA for the PHA Forum 2019 from 8 am - Noon on March 18, 2019 in Philadelphia, PA at the Loews Philadelphia hotel. Meet PHA Board Members, Industry Decision Makers, Innovators, Quality and Research and Policy Experts and network to make life long connections. 

Can't attend in person? Join the livestream! Learn more and view the agenda here

A special thank you to our sponsors:
Silver Sponsors:

Bronze Sponsors:


Just Announced! PHA Professional Membership

Month of March only join at 50% with code PHAMarch

PHA has expanded its membership with a new category of Professional Membership.  Directors and vice presidents of Population Health affiliated with hospitals, provider groups, academic institutions, employers, and regional health plans are eligible to join. PHA’s voting Corporate members key to transforming change in health care include health systems, health plans, employer solutions, academia, biopharma and technology and other solution companies.   

PHA Professional Member Benefits

Specific to a Professional Membership in PHA, individuals will benefit from: peer-to-peer dialogues; educational webinars with guest speakers from PHA’s prestigious Board; participation in idea-sharing forums; opportunity to be selected to participate in various forums and surveys; access to exclusive publications and reports; and, discounted registration at PHA events. 

PHA Thought Leadership - Don’t Miss This!

Look to our Chairman’s Leadership Circle for the latest thought provoking writings from the industry’s top thought leaders. If you would like to be considered as a contributor please email

ICYMI - PHA Provider Series Webinar: Planning for Success in Population Health – The Main Line Story

Dawn Tice RN, BSN, MBA  
Division Vice President, Clinical Operations 
Main Line Healthcare
Save the Date!

The PHA Innovation Summit and Capital Caucus 2019 will be held October 29th from 7am - 3pm at Top of the Hill in Washington, D.C. 

Contact to learn more.
Population Health Management

Population Health Management is the official journal for the Population Health Alliance. PHA corporate members receive a complimentary subscription. In a previous edition we had a full insert highlighting the PHA Value to Members

In future issues we will include the PHA Member Showcase where your company could be highlighted to the journal's more than 14,000 corporate and individual subscribers.

Please contact Allison King at or 202-737-5476 for more information on being featured in the PHA Member Showcase. 

Population Health Management’s editorial board is seeking manuscript submissions for review. Please review criteria and information for submission

PHA Members in the News
Solera Health and Fitbit Expand Partnership to Reduce Risk of Type 2 Diabetes

Solera Health, an integrated benefit network, and Fitbit, the leading global wearables brandannounced they have expanded their partnership to reduce the risk of type 2 diabetes by using the Fitbit platform through Solera Health’s innovative model to encourage positive behavior changes, such as increased physical activity and weight loss. Based on an analysis of more than 1,700 people who enrolled in the National Diabetes Prevention Program (DPP) through the Solera network, Solera found that participants who redeemed a Fitbit device were more active and lost more weight during the program than those who did not. Now, the companies are making the latest Fitbit devices, Fitbit Inspire™ and Inspire HR™, available to all Solera DPP participants, including Medicare and Medicaid beneficiaries. More

Geisinger Awarded Over $3.1 million for Research of Sudden Cardiac Death by The National Institutes of Health

The National Institutes of Health has awarded researchers at Geisinger $3.1 million over the next five years to explore innovative approaches for early, genomics-based detection of arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC is a degenerative heart disease responsible for approximately 20 percent of sudden cardiac death in individuals under age 35. Clinical symptoms of ARVC are frequently absent before a sudden death event, and it is often undetected in routine examinations. More

Blue Cross Blue Shield Association Proposes Steps to Cut Premiums 33 Percent and Increase Coverage

The Blue Cross Blue Shield Association (BCBSA) proposed a series of steps to reduce premiums for those who buy insurance through the individual market and expand access to coverage for more than 4 million additional people. More

Tufts Health Plan Adds Dermatology to Its Telehealth Solution Offering

Tufts Health Plan has added dermatology to its telehealth solution, providing their commercial members with access to a doctor, behavioral health therapist, or dermatologist 24-hours a day, seven days a week by web, phone, or mobile app— whether it be from the comfort of their home or while traveling. More

Capital BlueCross Tops Industry Average for Fifth Straight Year for Customer Satisfaction

Since 2014, Capital BlueCross has scored higher than all health insurance providers publicly measured in the American Customer Satisfaction Index (ACSI). On a scale of 0-100, with 100 being the most satisfied, Capital BlueCross' ACSI score is 79, the highest among health insurance providers tracked by the Index. More

Leavitt Partners Releases “Track Switching in Medicare ACO Programs: A Look at the Move to Downside Risk” White Paper

Leavitt Partners released “Track Switching in Medicare ACO Programs: A Look at the Move to Downside Risk,” a white paper providing data-driven insight into the important characteristics distinguishing ACOs that progress to downside risk tracks from those that do not. The analysis in this paper draws on Leavitt Partners Insight’s analytics solution Torch Insight (“Torch”). Torch is a robust, market-centric data integration and analytics platform that delivers reliable, comprehensive and actionable healthcare insights. More

Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

Amgen, Cytokinetics, Incorporated and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). More

Franciscan Health Surgeon First In World To Use Device

A patient who received a first-in-the-world tricuspid valve procedure as part of a new national clinical trial at Franciscan Health Heart Center is home and recovering well. More

NACDD Announces 2019 Walkability Action Institute Teams

The National Association of Chronic Disease Directors (NACDD), in collaboration with the Centers for Disease Control and Prevention’s (CDC) National Center for Chronic Disease Prevention and Health Promotion’s (NCCDPHP) Division of Nutrition, Physical Activity and Obesity (DNPAO), announces the 10 interdisciplinary regional teams that will receive travel assistance to attend the 2019 Step It Up!: Action Institute to Increase Walking and Walkability, also known as the Walkability Action Institute (WAI) in Decatur, Ga., April 22-25. More

Twenty-One Vendors Earn NCQA’s Measure Certification

The National Committee for Quality Assurance (NCQA) certified 21 vendors for their software code that produces administrative measure results related to the Healthcare Effectiveness Data and Information Set (HEDIS®). HEDIS, is of course, the nation’s most widely-used health quality data set. More

Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials

Merck announced the presentation of interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with various agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). These early findings show anti-tumor activity across three cohorts of the study, which investigated KEYTRUDA in combination with LYNPARZA (Cohort A, Abstract #145); docetaxel and prednisone (Cohort B, Abstract #170); and enzalutamide (Cohort C, Abstract #171) – with a safety profile consistent with each therapy alone. These results are being presented today at the 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco. Based on the findings, Merck is initiating three new pivotal Phase 3 trials with KEYTRUDA in combination with LYNPARZA (KEYLYNK-010, NCT03834519), docetaxel and prednisone (KEYNOTE-921, NCT03834506) and enzalutamide (KEYNOTE-641, NCT03834493). More

If you would like to have your PHA member company featured in Population Health in the News contact Allison King at (202) 737-5476 
The PHA Board thanks its many committed members advancing Population Health for individuals and communities every day.  If you are not a PHA member join the Population Health Alliance today.
Twitter LinkedIn
powered by emma
Subscribe to our email list.